Hikma and Arecor in US injectable medicine deal

9 January 2020
hikma-big

London-listed Hikma Pharmaceuticals (LSE: HIK) and UK company Arecor have agreed to co-develop a new, ready-to-use injectable medicine in the USA.

The product, which will be announced prior to launch, is being developed using Arecor’s drug formulation technology platform Arestat, which enhances the properties of approved therapeutic proteins and peptides to deliver new reformulations of existing, complex products.

Filing in 2021

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics